



**Australian Government**  
**Department of Health**  
**Therapeutic Goods Administration**

## Public Summary

|                                |                                                 |                                   |
|--------------------------------|-------------------------------------------------|-----------------------------------|
| <b>Summary for ARTG Entry:</b> | 314590                                          | Blackmores Joint Formula Advanced |
| <b>ARTG entry for</b>          | Medicine Listed                                 |                                   |
| <b>Sponsor</b>                 | Blackmores Ltd                                  |                                   |
| <b>Postal Address</b>          | PO Box 1725, WARRIEWOOD, NSW, 2102<br>Australia |                                   |
| <b>ARTG Start Date</b>         | 20/02/2019                                      |                                   |
| <b>Product Category</b>        | Medicine                                        |                                   |
| <b>Status</b>                  | Active                                          |                                   |
| <b>Approval Area</b>           | Listed Medicines                                |                                   |

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1. Blackmores Joint Formula Advanced

|                     |                         |                       |           |
|---------------------|-------------------------|-----------------------|-----------|
| <b>Product Type</b> | Single Medicine Product | <b>Effective Date</b> | 9/09/2021 |
|---------------------|-------------------------|-----------------------|-----------|

### Permitted Indications

Maintain/support general health and wellbeing

Maintain/support bone health

Aids/assists healthy bone development/growth/building

Help maintain/support bone mineralisation

Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis

Linked indication - Decrease/reduce/relieve mild joint aches and pains

Linked indication - Helps maintain/supports healthy joint cartilage growth/development/production

Linked indication - Maintain/support joint health

Linked indication - Decrease/reduce/relieve mild joint stiffness

Linked indication - Maintain/support joint mobility/flexibility

Linked indication - Decrease/reduce/relieve mild joint pain/soreness

Linked indication - Decrease/reduce/relieve mild joint inflammation/swelling

### Indication Requirements

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must only refer to mild joint symptoms.

### Standard Indications

No Standard Indications included on Record

### Specific Indications

No Specific Indications included on Record

### Warnings

Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet.

The recommended daily dose of this medicine contains [state quantity and units] of sodium (or words to that effect).

If symptoms persist consult your healthcare practitioner (or words to that effect).

### Additional Product information



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1 . Formulation 1**

**Dosage Form** Tablet, film coated

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

|                                            |                |
|--------------------------------------------|----------------|
| <b>borax</b>                               | <b>8.83 mg</b> |
| Equivalent: boron                          | 1 mg           |
| <b>bovine sodium chondroitin sulfate</b>   | <b>400 mg</b>  |
| <b>glucosamine sulfate sodium chloride</b> | <b>942 mg</b>  |
| Equivalent: glucosamine sulfate            | 750 mg         |
| <b>manganese gluconate</b>                 | <b>8.77 mg</b> |
| Equivalent: manganese                      | 1 mg           |

**Other Ingredients (Excipients)**

carmellose sodium  
colloidal anhydrous silica  
croscarmellose sodium  
Flavour  
glucose monohydrate  
hypromellose  
lecithin  
macrogol 3350  
magnesium stearate  
maltodextrin  
microcrystalline cellulose  
povidone  
titanium dioxide  
xylitol

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary